Emerging Targets for Drug Addiction Treatment

Resource Information

The instance Emerging Targets for Drug Addiction Treatment represents a material embodiment of a distinct intellectual or artistic creation found in University of Missouri-St. Louis Libraries. This resource is a combination of several types including: Instance, Electronic.

Image

http://images.btol.com/ContentCafe/Jacket.aspx?UserID=ebsco-test&Password=ebsco-test&Return=T&Value=9781620819548&Type=L

Label

Emerging Targets for Drug Addiction Treatment

Instantiates

• Emerging Targets for Drug Addiction Treatment

Publication

• Hauppauge, Nova Science Publishers, Inc., 2012

Note

Chapter 6: PSYCHOSOCIAL AND PHARMACOLOGICAL TREATMENTS FOR BEHAVIORAL ADDICTIONS

Bibliography note

Includes bibliographical references and index

Carrier category

online resource

Carrier category code

• cr

Carrier MARC source

rdacarrier

Content category

text

Content type code

• txt

Content type MARC source

rdacontent

Contents

• EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine)
• 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy
• 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES
• 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES
• Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES

Control code

898103608

Dimensions

unknown

Extent

1 online resource (240 pages).

Form of item

online

Isbn

9781620819548

Media category

computer

Media MARC source

rdamedia

Media type code

• c

Record ID

.b13186094x

Specific material designation

remote

System control number

(OCoLC)898103608